Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2011

Open Access 01-03-2011

Tumor immunosurveillance in human cancers

Authors: Bernhard Mlecnik, Gabriela Bindea, Franck Pagès, Jérôme Galon

Published in: Cancer and Metastasis Reviews | Issue 1/2011

Login to get access

Abstract

Until now, the anatomic extent of tumor (TNM classification) has been by far the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients’ disease-free and overall survival. Tumoral and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. The density and the immune cell location within the tumor have a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host-immune reaction. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice.
Literature
1.
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., et al. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology, 24, 5313–5327.PubMedCrossRef
2.
Sobin, L., & Wittekind, C. (2002). TNM classification of malignant tumors (6th ed.). New York: Wiley-Liss.
3.
Weitz, J., Koch, M., Debus, J., Hohler, T., Galle, P. R., & Buchler, M. W. (2005). Colorectal cancer. Lancet, 365, 153–165.PubMedCrossRef
4.
Kumar, T., Patel, N., & Talwar, A. (2010). Spontaneous regression of thoracic malignancies. Respiratory Medicine, 104, 1543–1550.PubMedCrossRef
5.
Kalialis, L. V., Drzewiecki, K. T., & Klyver, H. (2009). Spontaneous regression of metastases from melanoma: Review of the literature. Melanoma Research, 19, 275–282.PubMedCrossRef
6.
Bir, A. S., Fora, A. A., Levea, C., & Fakih, M. G. (2009). Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer Research, 29, 465–468.PubMed
7.
Bindea, G., Mlecnik, B., Fridman, W. H., Pages, F., & Galon, J. (2010). Natural immunity to cancer in humans. Current Opinion in Immunology, 22, 215–222.PubMedCrossRef
8.
Pages, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautes-Fridman, C., & Fridman, W. H. (2010). Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene, 29, 1093–1102.PubMedCrossRef
9.
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960–1964.PubMedCrossRef
10.
Galon, J., Fridman, W. H., & Pages, F. (2007). The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Research, 67, 1883–1886.PubMedCrossRef
11.
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.H., Pages, F., et al. (2011) Histopathological-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol ( in press)
12.
Bird, N. C., Mangnall, D., & Majeed, A. W. (2006). Biology of colorectal liver metastases: A review. Journal of Surgical Oncology, 94, 68–80.PubMedCrossRef
13.
Rudmik, L. R., & Magliocco, A. M. (2005). Molecular mechanisms of hepatic metastasis in colorectal cancer. Journal of Surgical Oncology, 92, 347–359.PubMedCrossRef
14.
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006). Colorectal cancer: Genetics of development and metastasis. Journal of Gastroenterology, 41, 185–192.PubMedCrossRef
15.
Cardoso, J., Boer, J., Morreau, H., & Fodde, R. (2007). Expression and genomic profiling of colorectal cancer. Biochimica et Biophysica Acta, 1775, 103–137.PubMed
16.
Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., et al. (2003). Osteopontin identified as colon cancer tumor progression marker. Comptes Rendus Biologies, 326, 1041–1043.PubMedCrossRef
17.
Arango, D., Laiho, P., Kokko, A., Alhopuro, P., Sammalkorpi, H., Salovaara, R., et al. (2005). Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology, 129, 874–884.PubMedCrossRef
18.
Barrier, A., Lemoine, A., Boelle, P. Y., Tse, C., Brault, D., Chiappini, F., et al. (2005). Colon cancer prognosis prediction by gene expression profiling. Oncogene, 24, 6155–6164.PubMedCrossRef
19.
Bertucci, F., Salas, S., Eysteries, S., Nasser, V., Finetti, P., Ginestier, C., et al. (2004). Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 23, 1377–1391.PubMedCrossRef
20.
D’Arrigo, A., Belluco, C., Ambrosi, A., Digito, M., Esposito, G., Bertola, A., et al. (2005). Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. International Journal of Cancer, 115, 256–262.CrossRef
21.
Dan, S., Tsunoda, T., Kitahara, O., Yanagawa, R., Zembutsu, H., Katagiri, T., et al. (2002). An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Research, 62, 1139–1147.PubMed
22.
Hegde, P., Qi, R., Gaspard, R., Abernathy, K., Dharap, S., Earle-Hughes, J., et al. (2001). Identification of tumor markers in models of human colorectal cancer using a 19, 200-element complementary DNA microarray. Cancer Research, 61, 7792–7797.PubMed
23.
Koehler, A., Bataille, F., Schmid, C., Ruemmele, P., Waldeck, A., Blaszyk, H., et al. (2004). Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. The Journal of Pathology, 204, 65–74.PubMedCrossRef
24.
Komuro, K., Tada, M., Tamoto, E., Kawakami, A., Matsunaga, A., Teramoto, K., et al. (2005). Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. The Journal of Surgical Research, 124, 216–224.PubMedCrossRef
25.
Kwon, H. C., Kim, S. H., Roh, M. S., Kim, J. S., Lee, H. S., Choi, H. J., et al. (2004). Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Diseases of the Colon and Rectum, 47, 141–152.PubMedCrossRef
26.
Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., et al. (2004). Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. Journal of Clinical Oncology, 22, 1564–1571.PubMedCrossRef
27.
Weigelt, B., Glas, A. M., Wessels, L. F., Witteveen, A. T., Peterse, J. L., & van’t Veer, L. J. (2003). Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 100, 15901–15905.PubMedCrossRef
28.
Al-Mulla, F., Keith, W. N., Pickford, I. R., Going, J. J., & Birnie, G. D. (1999). Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes, Chromosomes & Cancer, 24, 306–314.CrossRef
29.
Mehta, K. R., Nakao, K., Zuraek, M. B., Ruan, D. T., Bergsland, E. K., Venook, A. P., et al. (2005). Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clinical Cancer Research, 11, 1791–1797.PubMedCrossRef
30.
Tanami, H., Tsuda, H., Okabe, S., Iwai, T., Sugihara, K., Imoto, I., et al. (2005). Involvement of cyclin D3 in liver metastasis of colorectal cancer, revealed by genome-wide copy-number analysis. Laboratory Investigation, 85, 1118–1129.PubMedCrossRef
31.
Bardelli, A., Saha, S., Sager, J. A., Romans, K. E., Xin, B., Markowitz, S. D., et al. (2003). PRL-3 expression in metastatic cancers. Clinical Cancer Research, 9, 5607–5615.PubMed
32.
Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., St Croix, B., et al. (2001). A phosphatase associated with metastasis of colorectal cancer. Science, 294, 1343–1346.PubMedCrossRef
33.
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109–1113.PubMedCrossRef
34.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467, 1114–1117.PubMedCrossRef
35.
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual Review of Immunology, 22, 329–360.PubMedCrossRef
36.
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006). Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology, 90, 1–50.PubMedCrossRef
37.
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107–1111.PubMedCrossRef
38.
Birkeland, S. A., Storm, H. H., Lamm, L. U., Barlow, L., Blohme, I., Forsberg, B., et al. (1995). Cancer risk after renal transplantation in the Nordic countries, 1964–1986. International Journal of Cancer, 60, 183–189.CrossRef
39.
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006). Interferons, immunity and cancer immunoediting. Nature Reviews. Immunology, 6, 836–848.PubMedCrossRef
40.
MacKie, R. M., Reid, R., & Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. The New England Journal of Medicine, 348, 567–568.PubMedCrossRef
41.
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nature Reviews. Cancer, 8, 299–308.PubMedCrossRef
42.
Schon, M. P., & Schon, M. (2008). TLR7 and TLR8 as targets in cancer therapy. Oncogene, 27, 190–199.PubMedCrossRef
43.
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450, 903–907.PubMedCrossRef
44.
Atreya, I., & Neurath, M. F. (2008). Immune cells in colorectal cancer: Prognostic relevance and therapeutic strategies. Expert Review of Anticancer Therapy, 8, 561–572.PubMedCrossRef
45.
46.
Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England Journal of Medicine, 353, 2654–2666.PubMedCrossRef
47.
Camus, M., Tosolini, M., Mlecnik, B., Pages, F., Kirilovsky, A., Berger, A., et al. (2009). Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Research, 69, 2685–2693.PubMedCrossRef
48.
Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., et al. (2010). Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology, 138, 1429–1440.PubMedCrossRef
49.
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., et al. (2009). ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics, 25, 1091–1093.PubMedCrossRef
50.
Pages, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., et al. (2009). In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of Clinical Oncology, 27, 5944–5951.PubMedCrossRef
51.
Dalerba, P., Maccalli, C., Casati, C., Castelli, C., & Parmiani, G. (2003). Immunology and immunotherapy of colorectal cancer. Critical Reviews in Oncology/Hematology, 46, 33–57.PubMedCrossRef
52.
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annual Review of Immunology, 22, 745–763.PubMedCrossRef
53.
Xiang, R., Lode, H. N., Gillies, S. D., & Reisfeld, R. A. (1999). T cell memory against colon carcinoma is long-lived in the absence of antigen. Journal of Immunology, 163, 3676–3683.
54.
Croker, A. K., & Allan, A. L. (2008). Cancer stem cells: Implications for the progression and treatment of metastatic disease. Journal of Cellular and Molecular Medicine, 12, 374–390.PubMedCrossRef
55.
Uhr, J. W., & Marches, R. (2001). Dormancy in a model of murine B cell lymphoma. Seminars in Cancer Biology, 11, 277–283.PubMedCrossRef
56.
Vessella, R. L., Pantel, K., & Mohla, S. (2007). Tumor cell dormancy: An NCI workshop report. Cancer Biology & Therapy, 6, 1496–1504.CrossRef
57.
Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews. Cancer, 7, 834–846.PubMedCrossRef
58.
Clemente, C. G., Mihm, M. C., Jr., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77, 1303–1310.PubMedCrossRef
59.
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348, 203–213.PubMedCrossRef
60.
Schumacher, K., Haensch, W., Roefzaad, C., & Schlag, P. M. (2001). Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Research, 61, 3932–3936.PubMed
61.
House, A. K., & Watt, A. G. (1979). Survival and the immune response in patients with carcinoma of the colorectum. Gut, 20, 868–874.PubMedCrossRef
62.
Svennevig, J. L., Lunde, O. C., Holter, J., & Bjorgsvik, D. (1984). Lymphoid infiltration and prognosis in colorectal carcinoma. British Journal of Cancer, 49, 375–377.PubMedCrossRef
63.
Jass, J. R. (1986). Lymphocytic infiltration and survival in rectal cancer. Journal of Clinical Pathology, 39, 585–589.PubMedCrossRef
64.
Halvorsen, T. B., & Seim, E. (1989). Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. Journal of Clinical Pathology, 42, 162–166.PubMedCrossRef
65.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Research, 58, 3491–3494.PubMed
66.
Kirkwood, J. M., & Tarhini, A. A. (2009). Biomarkers of therapeutic response in melanoma and renal cell carcinoma: Potential inroads to improved immunotherapy. Journal of Clinical Oncology, 27, 2583–2585.PubMedCrossRef
67.
Gajewska, B. U., Alvarez, D., Vidric, M., Goncharova, S., Stampfli, M. R., Coyle, A. J., et al. (2001). Generation of experimental allergic airways inflammation in the absence of draining lymph nodes. Journal of Clinical Investigation, 108, 577–583.PubMed
68.
Halama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., von Knebel Doeberitz, M., et al. (2009). The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immunology, 9, 1.
Metadata
Title
Tumor immunosurveillance in human cancers
Authors
Bernhard Mlecnik
Gabriela Bindea
Franck Pagès
Jérôme Galon
Publication date
01-03-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9270-7

Other articles of this Issue 1/2011

Cancer and Metastasis Reviews 1/2011 Go to the issue

OriginalPaper

Tumor immune surveillance and ovarian cancer

OriginalPaper

The significant role of mast cells in cancer

Acknowledgments

Biography — Wolf H. Fridman, M.D., Ph.D.

OriginalPaper

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

OriginalPaper

Myeloid cell diversification and complexity: an old concept with new turns in oncology

EditorialNotes

Preface
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits